Bioidentical Hormone Replacement
Therapy (BHRT) Research

Hormonal replacement therapy is approved to treat hot flashes, vaginal dryness, and to prevent osteoporosis. Currently this treatment is not promoted as a treatment to prevent heart disease, cancer, or as an anti-aging strategy. However, research exists that suggests hormonal replacement, when done safely and with the bioidentical forms, might provide many health benefits outside of just controlling symptoms of PMS, menopause, or andropause.

Everyone wants to know, however, is BHRT safe? Are the risks the same as with synthetic hormonal therapy?

Read below to learn more about what the research is saying at this point:

BHRT and Heart Health

  • Bioidentical progesterone might increase “good cholesterol” or HDL levels, whereas synthetic progestins cause a decrease in “good cholesterol” : Saarikoski 1983/ Ottosson 1985
  • Natural progesterone significantly enhances effect of estrogen on exercise induced heart muscle damage in post-menopausal women with coronary artery disease: Rosano 2000
  • Estradiol and progesterone or MPA protects again coronary spasm, improving vascular function in rhesus monkeys: Minshall 1998
  • Women with severe hot flashes have a higher risk for heart disease: Franco 2015

BHRT and Osteoporosis

  • Transdermal estradiol is an effective treatment to improve bone mineral density and reduce further fractures in post-menopausal women with osteoporosis: Lufkin 2009
  • Estrogen-treated patients whose therapy started within 3 years of menopause showed improvement or no increase in osteoporosis: Nachtigall 1979
  • Continuous low-dose HRT combined with adequate calcium and vitamin D provides a bone-sparing effect that is similar or superior to that provided by other, higher-dose HRT regimens in elderly women: Recker 1999

BHRT and Breast Cancer

  • No risk of breast cancer in patients using combination estrogen and progesterone vs using synthetic estrogen alone.
    Fournier 2008
  • Risk for breast cancer was significantly increased if synthetic progestins were used but reduced if progesterone was used: Fournier 2005
  • Compared to placebo, increased breast tissue growth with estrogen and MPA, but not seen with combination of estrogen and progesterone: Wood 2007
  • 10 times as many deaths in low progesterone group compared to normal levels: Cowan 1981
  • Progesterone level was inversely associated with breast cancer risk for highest versus lowest tertitle: Micheli 2004
  • Progesterone reduced estradiol induced breast cell proliferation in vivo: Foidart 1998
  • Rransdermal hormones were not associated with venous thromboembolism. Synthetic oral forms increased the risk of thromboembolism 4 fold: Canonico 2007
  • Data does not show an increased risk of cancer recurrence among women currently undergoing treatment for breast cancer or those with a personal history of breast cancer who use vaginal estrogen to relieve urogenital symptoms: American College of Obstetricians and Gynecologists Committee March 2016
  • Topical estrogen does not seem to be associated with an increased risk of recurrence of breast cancer: Dew 2009

BHRT Overall Safety

Physiological data and clinical outcomes demonstrate that bioidentical hormones are associated with lower risks, including the risk of breast cancer and cardiovascular disease, and are more efficacious than their synthetic and animal-derived counterparts. Until evidence is found to the contrary, bioidentical hormones remain the preferred method of HRT. Further randomized controlled trials are needed to delineate these differences more clearly: Holtorf 2015

Books & Resources:

Click on the book image to order through